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Abstract
Background: Chemokines immobilized on endothelial cells play a central role in the induced firm
adhesion and transendothelial migration of leukocytes. Activation of platelets at sites of vascular
injury is considered to support leukocyte adhesion and extravasation. However, activated platelets
also secrete soluble glycosaminoglycans that can interfere with immobilization of chemokines. We
therefore analyzed the impact of platelet derived glycosaminoglycans on the immobilization of the
chemokine CCL5 (RANTES) on human microvascular endothelial cells and their influence on
CCL5-CCR5 interactions.
Results: We confirm that undiluted serum in contrast to plasma decreases binding of CCL5 to
endothelial cells. However, when lower concentrations of serum were used, CCL5-presentation
on endothelial cells was markedly enhanced. This enhancement was neutralized if serum was
digested with chondroinitase ABC. Using different chondroitinsulfate-subtypes we demonstrate
that chondroitinsulfate A mediates the enhanced presentation of CCL5 on endothelial cells,
whereas chondroitinsulfate B/C even at low concentrations block CCL5 binding. CCR5
downregulation on CCR5-transfected CHO cells or human monocytes is increased by
preincubation of CCL5 with serum or chondroitinsulfate A.
Conclusion: We show that chondroitinsulfate A released from platelets increases the binding of
chemokines to endothelial cells and supports receptor internalization in a dose dependent manner.
These data help to understand the proinflammatory effects of activated platelets.
Background
The adhesion and transendothelial migration of leuko-
cytes is largely dependent on chemokines and adhesion
molecules. In order to support leukocyte recruitment
chemokines need to be immobilized on the luminal sur-
face of the endothelial cell wall. Within tissues leukocytes
are also directed by gradients of chemokines [1]. By inter-
acting with different chemokine receptors (CCR1 and
CCR5) the chemokine CCL5 (RANTES) has been shown
to be involved in several steps of leukocyte recruitment
[2].
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Chemokines can gain access to the luminal site of the
endothelium by transcytosis through endothelial cells [3],
after release from circulating leukocytes or after secretion
from activated endothelial cells [4]. Platelets have been
identified as important source of chemoattractant factors
such as CCL5 [5], but also release substantial amounts of
chondroitinsulfate A [6]. In vivo, platelet activation and
adhesion occurs at sites of vascular injury and facilitates
leukocyte recruitment [7-10].
It has been shown that membrane bound gly-
cosaminoglycans are critically involved in immobiliza-
tion and presentation of chemokines [11-14]. Different
patterns of glycosaminoglycan expression on cells may
favor the binding of certain chemokines and thereby
influence the cellular composition of the inflammatory
response. However, chemokines also interact with soluble
glycosaminoglycans that compete with the binding of
chemokines to cell surfaces. Heparin has the highest affin-
ity to CCL5, followed by heparansulfate, chondroitinsul-
fate C, dermatansulfate (chondroitinsulfate B) and
chondroitinsulfate A [15]. We could demonstrate that
human serum inhibits CCL5 binding on CHO cells and
cultured human endothelial cells and could identify the
responsible serum factor as chondroitinsulfate A (CSA)
released from platelets after activation [16].
Glycosaminoglycans also alter the ability of chemokines
to interact with chemokine receptors. Soluble Gly-
cosaminoglycans have been shown to inhibit binding of
IL-8 to CXCR1 and CXCR2 and CCL3 to CCR1 [15]. It was
also shown that CCL5/glycosaminoglycan complexes are
able to bind to deglycated PBMC and thereby block HIV-
1 infection more effectively than CCL5 alone [17].
Activated platelets have been identified as a major source
of CSA in human serum [6]. In addition, release of chon-
droitinsulfate A was shown in activated T cells [18,19]. It
is commonly thought that interaction of chemokines with
soluble glycosaminoglycans reduces their ability to bind
to cell surfaces and interferes with leukocyte recruitment.
However, these results do not fit to the proinflammatory
effects caused by intravascular activation of platelets.
Therefore we analyzed in more detail the influence of
serum and various glycosaminoglycans on the binding of
CCL5 to endothelial cells and on the ability of CCL5 to
activate CCR5.
Results and discussion
Influence of serum and glycosaminoglycans on CCL5 
binding to endothelial cells
In previous experiments we have shown a reduced bind-
ing of CCL5 to cell surfaces after preincubation of CCL5
with human serum and have identified the responsible
serum factor as chondroitinsulfate A (CSA) released from
activated platelets. In these experiments we used undi-
luted or moderately diluted serum and high concentra-
tions of CSA [16]. The use of undiluted serum or high
concentrations of glycosaminoglycans may not reflect in
vivo settings of local inflammation where only a minor
proportion of total platelets are activated and release CSA.
We therefore analyzed the effects of serum or chondroitin-
sulfate A over a wide range of concentrations. CCL5 was
preincubated with decreasing concentrations of human
serum and then incubated with microvascular human
endothelial cells (MVEC) (Fig. 1). High concentrations of
serum block CCL5 binding to the surface of microvascular
endothelial cells confirming our previous results [16].
However, preincubation of CCL5 with lower concentra-
tions of serum resulted in a threefold higher binding of
CCL5 to endothelial cells (Fig. 1). Human plasma, that
does not contain CSA released from activated platelets,
was unable to increase the binding of CCL5 to endothelial
cells suggesting that platelet derived chondroitinsulfate A
might be a crucial factor. To demonstrate that chon-
droitinsulfate is responsible for the enhanced binding of
CCL5 in the presence of serum, serum was digested with
chondroinitase ABC before preincubation with CCL5.
Digested serum was no longer able to reduce or enhance
the binding of CCL5 (Fig. 2A). To determine which gly-
cosaminoglycan is responsible for this effect, we com-
pared the effect of CSA, CSB and CSC on CCL5 binding to
endothelial cells (Fig. 2B). Preincubation of CCL5 with
CSB and CSC resulted in a strong inhibition of chemokine
binding. No increased binding of CCL5 was detectable
even at low concentrations of these glycosaminoglycans.
In contrast, preincubation of CCL5 with low concentra-
tions of CSA resulted in a dose-dependent increase of the
binding of CCL5 (Fig. 2B). The most likely explanation for
the enhanced binding of CCL5 after exposure to low con-
centrations of CSA or serum is the occurrence of CCL5-
CSA complexes and their subsequent binding to surface
glycosaminoglycans via their CCL5 part or to surface
receptors for CSA via their CSA part. Among molecules
that are known to bind chondroitinsulfate A (CD36,
CD206 or CD44 [20,21]) only the proteoglycan CD44
was strongly expressed on cultured endothelial cells.
However, neither blockade of CD44 with a neutralizing
antibody (BRIC235 [22]) nor preincubation of cells with
serum, CSA, CSB or CSC altered the binding of CCL5 or
CCL5-CSA-complexes to the surface of endothelial cells
(data not shown). Therefore it seems unlikely that possi-
ble CSA binding sites on cell surfaces play an important
role in the process of chemokine immobilization. Instead,
we favor the hypothesis that CCL5-CSA complexes bind
primarily via CCL5 to glycosaminoglycans on the cell sur-
face. The low affinity between CCL5 and CSA may allow
the binding of CCL5-CSA complexes to glycosaminogly-
cans with high affinity for CCL5 (e.g. heparansulfate).
Surface heparansulfate proteoglycan expression is upregu-BMC Immunology 2008, 9:72 http://www.biomedcentral.com/1471-2172/9/72
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lated under proinflammatory conditions in osteosarcoma
cells [23]. To test the hypothesis that activation of
endothelial cells leads to an increased immobilization of
chemokines, cells were stimulated with TNF-α and IL-1β
for 48 hours. However, stimulation of endothelial cells
with TNF-α and IL-1β did not increase CCL5 immobiliza-
tion on primary human microvascular endothelial cells
(data not shown).
We also investigated if CCL5 bound to the surface of
endothelial cells could be removed from the cell surface
by incubation with an excess of soluble glycosaminogly-
cans. High doses of CSC (100 μg/ml) in contrast to CSA
resulted in a minor reduction (< 20%) of surface bound
CCL5 (data not shown).
Enhanced downregulation of CCR5 by CCL5-CSA 
complexes
To assess whether the interaction of CCL5 with CSA alters
the ability of CCL5 to activate CCR5, we performed recep-
tor downmodulation assays with CCR5 transfected CHO
cells and human PBMC isolated from peripheral blood
[24]. Surface expression of CCR5 was quantified by FACS
analysis. As shown in Figure 3A, downregulation of CCR5
on CHO cells was markedly enhanced if CCL5 was prein-
cubated with serum. Serum concentrations of between 1
% and 3 % resulted in the most pronounced enhance-
ment of CCL5 induced CCR5 downregulation compared
to CCL5 alone. Serum alone was not able to induce down-
regulation of CCR5 on transfected CHO cells (data not
shown). We also investigated CCL5-induced downmodu-
lation of CCR5 on human PBMC and analyzed CCR5 sur-
face expression on human monocytes by flow cytometry
(Fig. 3B). Preincubation of CCL5 with CSA resulted in a
more pronounced downmodulation of CCR5 from the
cell surface than preincubation of CCL5 with PBS. CSA
alone had no significant effect on CCR5 expression on
human monocytes. These data demonstrate that complex
formation of CCL5 with CSA not only increases the bind-
ing of CCL5 to cell surfaces but also enhances the ability
to interact with the chemokine receptor CCR5.
Conclusion
Activation of platelets at sites of vascular injury is consid-
ered as an important proinflammatory stimulus. Here we
show that chondroitinsulfate A released from activated
platelets has pronounced dose dependent effects on the
immobilization of CCL5 to endothelial cells and the
interaction of CCL5 with CCR5. Only at high concentra-
tions does platelet derived CSA block CCL5 binding to
endothelial cells, whereas at lower concentrations of CSA
the immobilization of CCL5 and its interaction with
CCR5 are markedly enhanced. Our data improve our
understanding of how activation of platelets may contrib-




Human microvascular endothelial cells (Promocell, Hei-
delberg, Germany) were cultured in MCDB 131 medium
(Invitrogen, Karlsruhe, Germany) with 15% FCS, hydro-
cortisone (1.2 μg/ml), epidermal growth factor (3 μg/l)
and L-glutamine (4 mmol/l). Where indicated endothelial
cells were stimulated for 48 h with TNF-α (10 ng/ml) and
IL-1β (5 ng/ml) (PeproTech, Rocky Hill, New Jersey USA).
CCR5 transfected CHO cells [24] were cultured in nucle-
otide free alpha-MEM medium containing 10% dialyzed
FCS. Human PBMC were isolated from healthy human
individuals by Ficoll-Paque density gradients and cultured
in RPMI medium (Invitrogen, Karlsruhe, Germany) for 24
hours to induce CCR5 expression on monocytes. Human
serum and plasma were obtained from healthy volunteers
using standard blood sample equipment. Plasma was
anticoagulated with EDTA. Where indicated serum was
digested for 2 hours at 37°C with chondroinitase ABC
(final concentration of 50 mU/mL; Sigma-Aldrich) in
RPMI 1640 medium.
Influence of human serum and plasma on the binding of  CCL5 to endothelial cells Figure 1
Influence of human serum and plasma on the binding 
of CCL5 to endothelial cells. CCL5 (1 μg/ml) was prein-
cubated with different concentrations of human serum (black 
bars) or human plasma (grey bars) and subsequently incu-
bated with human microvascular endothelial cells. Dilutions 
were performed with PBS. Binding of CCL5 to the cell sur-
face was quantified by FACS-analysis and is given as mean flu-
orescence intensity (MFI). Preincubation of CCL5 with low 
concentrations of serum significantly enhanced CCL5 bind-
ing, while preincubation with high concentrations of serum 
reduced CCL5 binding. Preincubation of CCL5 with plasma 
did not result in an increased immobilization of CCL5.BMC Immunology 2008, 9:72 http://www.biomedcentral.com/1471-2172/9/72
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Chondroitinsulfate A enhances the binding of CCL5 to endothelial cells Figure 2
Chondroitinsulfate A enhances the binding of CCL5 to endothelial cells. A) Digestion of serum with chondroinitase 
ABC abrogates the effects of serum on CCL5 binding. Serum was digested with chondroinitase ABC (grey bars) or left undi-
gested (black bars) and then incubated at different concentrations with human CCL5 (1 μg/ml). Subsequently, binding of CCL5 
to human microvascular endothelial cells was quantified by FACS-analysis and is given as mean fluorescence intensity (MFI). 
Undigested serum reduced or increased the binding of CCL5 in a concentration dependent manner, while digested serum did 
not alter CCL5 binding. Maximal reduction of CCL5 binding reached statistical significance (p = 0.03) compared to undigested 
serum. B) Influence of various types of chondroitinsulfate on the binding of CCL5 to human microvascular endothelial cells. 
CCL5 (1 μg/ml) was preincubated with different concentrations of chondroitinsulfate A (CSA), chondroitinsulfate B (CSB) or 
chondroitinsulfate C (CSC). Preincubation of CCL5 with low concentrations of CSA results in an significantly (p = 0.01) 
enhanced binding of CCL5 to endothelial cells, while preincubation of CCL5 with high concentrations of CSA or with CSB and 
CSC results in a reduced binding of CCL5.BMC Immunology 2008, 9:72 http://www.biomedcentral.com/1471-2172/9/72
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Enhanced downmodulation of CCR5 by preincubation of CCL5 with serum or CSA Figure 3
Enhanced downmodulation of CCR5 by preincubation of CCL5 with serum or CSA. A) CCL5 (1 μg/ml) was prein-
cubated with various concentrations of human serum diluted in PBS and then used to downmodulate CCR5 from CCR5-trans-
fected CHO cells. Low concentrations of serum significantly (p = 0.007) enhance the ability of CCL5 to downmodulate CCR5 
from the surface of CHO cells. Serum alone did not induce downmodulation of CCR5 from the surface of CHO cells (data not 
shown). B) CCL5 (0.3 μg/ml) was preincubated with various concentrations of CSA and then used to downmodulate CCR5 
from the surface of human monocytes. CSA alone did not affect CCR5 expression on monocytes (data not shown), but 
increased the CCL5-induced downmodulation of CCR5 significantly (p = 0.03).BMC Immunology 2008, 9:72 http://www.biomedcentral.com/1471-2172/9/72
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Binding of CCL5 to cell surfaces
Recombinant CCL5 (PeproTech, Rocky Hill, New Jersey
USA) was preincubated for 1 h on ice with PBS or different
concentrations of serum, plasma, chondroitinsulfate A
(CSA), chondroitinsulfate B (CSB) or chondroitinsulfate
C (CSC) (Sigma, St. Louis, USA) as indicated in the figure
legends. Cells were then incubated for 1 h on ice with
CCL5. After four washing steps with PBS, cells were
stained with a monoclonal antibody against CCL5 (VL-1,
10 μg/ml) (kindly provided by Dr. Nelson, Munich, Ger-
many) or a mouse IgG2b isotype control antibody
(Sigma-Aldrich, St. Louis, USA) followed by a phycoeryth-
rin-conjugated, rabbit anti-mouse F(ab)2 fragment
(DAKO, Glostrup, Denmark). Alternatively staining was
performed with a biotinylated antibody against CCL5
(clone VL-1, CALTAG, Burlingame, USA) followed by
allophycocyanin-conjugated Streptavidin (BD-Pharmin-
gen, Heidelberg, Germany). CCL5-binding was quantified
by flow cytometry using a FACSCalibur and cell quest
analysis software and is given as mean fluorescence inten-
sity (MFI) (Becton Dickinson, Heidelberg, Germany).
Experiments to detect or block CD44 were performed
with the anti-CD44 clone BRIC 235 (Bristol Institute for
Transfusion Sciences, Bristol, UK) at concentrations of 10
and 20 μg/ml respectively. Expression of CD206 (man-
nose receptor) and CD36 was measured with monoclonal
antibodies against CD206 (clone 19.2) and CD36 (clone
CB 38) by flow cytometry (BD-Pharmingen, Heidelberg,
Germany).
Downmodulation of CCR5
Downmodulation of CCR5 was performed as described
previously with minor modification [24]. CCL5 was pre-
incubated with serum or CSA as described above. CCR5
transfected CHO cells or PBMC were incubated at 37°C
for 2 hours with preincubated CCL5 (1 μg/ml) or with
PBS (pos. control) to induce receptor downmodulation.
Further steps were performed on ice to avoid receptor
recycling. CCR5 expression was measured by flow cytom-
etry using the monoclonal antibody MC-1 (10 μg/ml) or
an mouse IgG1 isotype control antibody (neg. control),
followed by a phycoerythrin-conjugated, rabbit anti-
mouse F(ab)2 fragment. Surface expression of CCR5 was
calculated as [mean fluorescence intensity (exp.) - mean
fluorescence (neg. control)]/[(mean fluorescence inten-
sity (pos. control.) - mean fluorescence (neg. control)].
Statistics
All experiments were reproduced at least two times and
single data points were obtained as mean values of dupli-
cates or triplicates. Error bars indicate the standard devia-
tion. Statistical differences of fluorescence intensities were
tested by using Student's t-test where appropriate.
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